Drug
OF Etc 1002
OF Etc 1002: highest development phase Phase 3, developed by Otsuka. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| 180mg of ETC-1002(bempedoic acid) NCT05687071 | Phase 3 | Hyper-low-density Lipoprotein (LDL) Cholesterolemia |
Latest
No recent events.
Follow OF Etc 1002 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.